You are here

Benefits Reported With VT-122 for Advanced Liver and Pancreatic Cancers

Initiation of registrational studies planned for this year

Two studies demonstrated a safety and survival benefit for VT-122 (Vicus Therapeutics) when combined with standard-of-care therapy in patients with advanced liver and pancreatic cancers, according to presentations at the 2015 Gastrointestinal Cancers Symposium in San Francisco.

VT-122 is a novel, chrono-modulated combination of the nonelective beta-adrenergic receptor blocker propranolol and the COX-2-selective nonsteroidal anti-inflammatory drug etodolac.

A phase 2 trial evaluated the safety, tolerability, and efficacy of VT-122 in patients with advanced hepatocellular carcinoma receiving sorafenib as standard-of-care, first-line therapy. The double-blind, multicenter study assessed 20 patients who were randomly assigned to receive either VT-122 (n = 11) or placebo (n = 9) on a background of stable-dose sorafenib (initiated 30 days prior to randomization).

Among patients treated with VT-122 plus sorafenib, 12-month survival was greater than that in patients treated with sorafenib alone (5 of 11 [45.5%] vs. 3 of  9 [27.3%]). Additionally, median overall survival (OS) increased by 2.0 to 4.4 months (8.8 to 13.2 months, data still maturing) in the VT-122-treated patients, compared to patients receiving sorafenib alone. Three patients treated with VT-122 have demonstrated durable responses. No treatment-associated serious adverse events were reported in the study.

In the second study, a single-center, open-label, investigator-led trial, 37 patients with advanced pancreatic cancer were randomly assigned to receive either VT-122 (n = 20) or placebo (n = 17) in addition to gemcitabine and a nanoparticle albumin-bound paclitaxel (GemNab). The VT-122 regimen was initiated one week prior to starting GemNab and then administered in combination with GemNab chemotherapy. Although follow-on lines of chemotherapy after disease progression were not administered, VT-122 treatment was continued after discontinuation of GemNab upon disease progression.

The use of VT-122 was associated with an increase in median OS of 7.7 months (9.3 to 17 months; hazard ratio, 0.10; 95% confidence interval, 0.035– 0.282; P < 0.001), compared to that observed with GemNab alone. Additionally, no treatment-associated serious adverse events were reported in the study.

The company expects to initiate approval-enabling phase 2 and 3 studies this year.

Source: Vicus Therapeutics; January 16, 2015. 

Recent Headlines

Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Antibiotics, Statins, and Glucocorticoids All Show Promise
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria
More Than 32% of Patients Responded in Trial
Evenity Increases New Bone Formation, Lowers Vertebral Fracture Potential